» Articles » PMID: 37627285

The Neurobiological Underpinnings of Obsessive-Compulsive Symptoms in Psychosis, Translational Issues for Treatment-Resistant Schizophrenia

Overview
Journal Biomolecules
Publisher MDPI
Date 2023 Aug 26
PMID 37627285
Authors
Affiliations
Soon will be listed here.
Abstract

Almost 25% of schizophrenia patients suffer from obsessive-compulsive symptoms (OCS) considered a transdiagnostic clinical continuum. The presence of symptoms pertaining to both schizophrenia and obsessive-compulsive disorder (OCD) may complicate pharmacological treatment and could contribute to lack or poor response to the therapy. Despite the clinical relevance, no reviews have been recently published on the possible neurobiological underpinnings of this comorbidity, which is still unclear. An integrative view exploring this topic should take into account the following aspects: (i) the implication for glutamate, dopamine, and serotonin neurotransmission as demonstrated by genetic findings; (ii) the growing neuroimaging evidence of the common brain regions and dysfunctional circuits involved in both diseases; (iii) the pharmacological modulation of dopaminergic, serotoninergic, and glutamatergic systems as current therapeutic strategies in schizophrenia OCS; (iv) the recent discovery of midbrain dopamine neurons and dopamine D1- and D2-like receptors as orchestrating hubs in repetitive and psychotic behaviors; (v) the contribution of N-methyl-D-aspartate receptor subunits to both psychosis and OCD neurobiology. Finally, we discuss the potential role of the postsynaptic density as a structural and functional hub for multiple molecular signaling both in schizophrenia and OCD pathophysiology.

Citing Articles

The safety and efficacy of N-acetylcysteine as an augmentation in the treatment of obsessive-compulsive disorder in adults: a systematic review and meta-analysis of randomized clinical trials.

Eghdami S, Eissazade N, Heidari Mokarar M, Boroon M, Orsolini L, Shalbafan M Front Psychiatry. 2024; 15:1421150.

PMID: 39376972 PMC: 11456833. DOI: 10.3389/fpsyt.2024.1421150.

References
1.
Klanker M, Feenstra M, Denys D . Dopaminergic control of cognitive flexibility in humans and animals. Front Neurosci. 2013; 7:201. PMC: 3817373. DOI: 10.3389/fnins.2013.00201. View

2.
Kapur S, Remington G . Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996; 153(4):466-76. DOI: 10.1176/ajp.153.4.466. View

3.
de Bartolomeis A, De Simone G, Ciccarelli M, Castiello A, Mazza B, Vellucci L . Antipsychotics-Induced Changes in Synaptic Architecture and Functional Connectivity: Translational Implications for Treatment Response and Resistance. Biomedicines. 2022; 10(12). PMC: 9776416. DOI: 10.3390/biomedicines10123183. View

4.
Denys D, Zohar J, Westenberg H . The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J Clin Psychiatry. 2004; 65 Suppl 14:11-7. View

5.
Welch J, Lu J, Rodriguiz R, Trotta N, Peca J, Ding J . Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. Nature. 2007; 448(7156):894-900. PMC: 2442572. DOI: 10.1038/nature06104. View